NPPA Sets New Retail Price for Cilnidipine, Telmisartan Combination
New Delhi: The National Pharmaceutical Pricing Authority (NPPA), under the Ministry of Chemicals and Fertilizers, has revised the retail price of the Fixed Dose Combination (FDC) drug containing Cilnidipine 20mg and Telmisartan 40mg following a review of data by the Department of Pharmaceuticals (DoP).
According to the notification issued by the Authority on February 7, 2025, the new retail price for the Cilnidipine & Telmisartan tablet (film-coated, 20mg/40mg) has been set at Rs14.15 per tablet. This update supersedes earlier pricing orders and is now applicable to the formulation manufactured by Akums Drugs & Pharmaceuticals Ltd. and marketed by Glenmark Pharmaceuticals Ltd.
The formulation combines two active ingredients, Cilnidipine, a calcium channel blocker, and Telmisartan, an angiotensin II receptor antagonist. It is commonly prescribed for the treatment of hypertension (high blood pressure) and chronic heart failure. By working together, these drugs help to relax blood vessels and improve blood flow, making it easier for the heart to pump blood and reducing the risk of heart attack or stroke.
Table
S. No. | Name of the Formulation | Dosage form & Strength | Unit | Retail Price (Rs.) | DoP Review no. & Date | Existing SO number & date | Manufacturer & Marketing Company respectively |
(1) | (2) | (3) | (4) | (5) | (6) | (7) | (8) |
1. | Cilnidipine & Telmisartan Tablets | Each film coated tablet contains: Cilnidipine IP 20mg Telmisartan IP 40mg | 1 Tablet | 14.15 | 31015/60/2023Pricing dated 04.10.2024 | 1434(E) dated 27.03.2023 (at Sl. No.22) | M/s Akums Drugs & Pharmaceuticals Ltd. / M/s Glenmark Pharmaceuticals Limited |
The notification further added that;
(a) The manufacturer as specified in column (8), of the above mentioned formulations i.e. “new drug” under paragraph 2(1)(u) of the DPCO, 2013 may revise the retail price as specified in column (5) of the table hereinabove.
(b) The manufacturer may add Goods and Services Tax only if they have paid actually or it is payable to the Government on the retail price mentioned in column (5) of the above said table.
(c) The retail price for a pack of the aforesaid formulation shall be arrived at by the concerned manufacturer in accordance with the retail price specified in column (5) of the above table as per provisions contained in paragraph 11 of the DPCO, 2013. The manufacturer shall issue a price list in Form–V from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State Drug Controller and dealers.
(d) As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business in a manner so as to be easily accessible to any person wishing to consult the same.
(e) The above mentioned retail prices are applicable only to the manufacturer / marketer as mentioned above for generic / any brand of the same composition / strength of the subject formulations, subject to fulfilment of all the applicable statutory requirements as laid down by the Govt. under relevant statutes/ rules, including manufacturing license permission from the Competent Authority i.e. the Central/State Licensing Authority, as may be applicable, by the concerned manufacturers/marketing companies.
(f) In case the retail price of any of the aforesaid formulations is not complied with, as per instant price notification and notes specified hereinabove, then the concerned manufacturer/marketing company shall be liable to deposit the overcharged amount along with the interest thereon under the provisions of the DPCO, 2013 read with the Essential Commodities Act, 1955.
(g) Consequent to the fixation of retail price of such formulation as specified in column (2) of the above table with the strength and name of Manufacturer & Marketing Companies specified in the corresponding entries in Column (3) & (8) thereof, the price order(s) fixing the retail price of the formulation with specified strength for that Manufacturer & Marketing Companies as specified in corresponding entries in Column (2), (3) and (8) thereof, if any, issued prior to this notification, stand(s) superseded.
